2-氯-4-甲氧基苯甲酸 | 21971-21-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-甲氧基苯甲酸
• 中文别名: 2-氯-对甲氧基苯甲酸
• 英文名称: 2-chloro-4-methoxybenzoic acid
• 英文别名: 2-Chlor-4-methoxy-benzoesaeure
• CAS: 21971-21-1
• 化学式: C₈H₇ClO₃
• 分子量: 186.595
• InChiKey: IBANGHTVBPZCHF-UHFFFAOYSA-N

物化性质

• 熔点：
  210.0 to 214.0 °C
• 沸点：
  303.0±22.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（轻微溶解、加热、超声处理）、DMSO（轻微溶解）、甲醇（轻微溶解、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Chloro-4-methoxybenzoic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Chloro-4-methoxybenzoic acid
Ingredient name:
CAS number: 21971-21-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7ClO3
Molecular weight: 186.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-甲氧基苯甲酸 在 氢氧化钾 、 乙醇 、 硫酸 、 铜 作用下， 生成 3-甲氧基氧杂蒽-9-酮
  参考文献：
  名称：

  Ullmann; Wagner, Justus Liebigs Annalen der Chemie, 1907, vol. 355, p. 366

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-4-甲氧基-苯甲酸甲酯 在 LiOH 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 以1.0 g (98%)的产率得到2-氯-4-甲氧基苯甲酸
  参考文献：
  名称：

  Therapeutic compounds

  摘要：

  描述了用作雌激素受体β选择性配体的化合物的公式(I)，其中：X为O或S；R1，R3和R6如规范中所述。描述了这些化合物在治疗阿尔茨海默病、焦虑症、抑郁症、骨质疏松症、心血管疾病、类风湿性关节炎和前列腺癌中的用途；以及制备它们的过程。

  公开号：

  US20040102435A1

文献信息

• [EN] MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021191359A1

  公开（公告）日：2021-09-30

  Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: (I) wherein R1a, R1b, R2, and R3, are defined herein.

  化合物的融合和桥联化合物的化学式(I)，以及其药用可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和症状的方法，例如与疼痛、精神紊乱、神经紊乱（包括但不限于重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、亚斯伯格综合症、双相情感障碍）、癌症和眼部疾病相关的方法：(I)其中R1a、R1b、R2和R3在此定义。
• TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
  申请人：Incyte Corporation

  公开号：US20210171535A1

  公开（公告）日：2021-06-10

  The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

  本公开涉及三环杂环化合物及其药物组合物，这些化合物是FGFR酶的抑制剂，可用于治疗FGFR相关疾病，如癌症。
• De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX
  作者：Joanne Tan、Julie J. Grouleff、Yulia Jitkova、Diego B. Diaz、Elizabeth C. Griffith、Wenjie Shao、Anastasia F. Bogdanchikova、Gennady Poda、Aaron D. Schimmer、Richard E. Lee、Andrei K. Yudin

  DOI：10.1021/acs.jmedchem.9b00878

  日期：2019.7.11

  facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.

  由于硼具有调节酶功能的能力，硼酸已引起合成化学和药物化学家的关注。最近，我们证明了含硼的两性构件可以促进生物活性氨基硼酸的发现。在此，我们通过从头开始的文库设计和针对共价配体进行了修改的虚拟筛选平台来增强了此功能。这项技术使我们能够快速设计和鉴定一系列α-氨基硼酸作为人类ClpXP的第一种抑制剂，这是导致错误折叠的蛋白质降解的原因。
• Iron-Catalyzed <i>Ortho</i> C–H Methylation of Aromatics Bearing a Simple Carbonyl Group with Methylaluminum and Tridentate Phosphine Ligand
  作者：Rui Shang、Laurean Ilies、Eiichi Nakamura

  DOI：10.1021/jacs.6b06908

  日期：2016.8.17

  (Me2N-TP), that allows us to convert an ortho C-H bond to a C-CH3 bond in aromatics and heteroaromatics bearing simple carbonyl groups under mild oxidative conditions. The reaction is powerful enough to methylate all four ortho C-H bonds in benzophenone. The reaction tolerates a variety of functional groups, such as boronic ester, halide, sulfide, heterocycles, and enolizable ketones.

  近年来，芳烃的铁催化 CH 官能化引起了化学家的广泛关注，但由于需要在底物上精心设计导向基团，迄今为止阻碍了苯甲酸和酮等简单芳香羰基化合物的使用，大大减少了其合成公用事业。我们在这里描述了温和反应性甲基铝试剂和用于金属催化的新三齿膦配体 4-(双(2-(二苯基膦基)苯基)膦基)-N,N-二甲基苯胺 (Me2N-TP) 的组合，这使我们能够在温和的氧化条件下将带有简单羰基的芳烃和杂芳烃中的邻位 CH 键转化为 C-CH3 键。该反应足够强大，可以甲基化二苯甲酮中的所有四个邻位 CH 键。该反应耐受多种官能团，如硼酸酯、
• [EN] N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP1, TLL1 AND/OR TLL2 INHIBITORS<br/>[FR] COMPOSÉS N-HYDROXYFORMAMIDES ET COMPOSITIONS LES COMPRENANT POUR UNE UTILISATION COMME INHIBITEURS DE BMP1, TLL1 ET/OU TLL2
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017006296A1

  公开（公告）日：2017-01-12

  Compounds of Formulas (I) and (II) and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

  公式（I）和（II）的化合物及其盐；制备和使用这些化合物的方法，包括用于抑制BMP1、TLL1和/或TLL2以及治疗与BMP1、TLL1和/或TLL2活性相关的疾病的用途。